Temasek Holdings Private Ltd Decreases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Temasek Holdings Private Ltd trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,057,248 shares of the medical research company’s stock after selling 13,932 shares during the period. Thermo Fisher Scientific accounts for 2.2% of Temasek Holdings Private Ltd’s investment portfolio, making the stock its 14th biggest holding. Temasek Holdings Private Ltd’s holdings in Thermo Fisher Scientific were worth $550,012,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Cypress Advisory Group LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at $253,000. Intact Investment Management Inc. raised its position in Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after acquiring an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $1,121,000. Clear Harbor Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 10.4% during the 4th quarter. Clear Harbor Asset Management LLC now owns 13,418 shares of the medical research company’s stock worth $6,981,000 after purchasing an additional 1,269 shares during the period. Finally, Fifth Third Bancorp increased its holdings in shares of Thermo Fisher Scientific by 11.6% during the 4th quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company’s stock valued at $174,305,000 after purchasing an additional 34,917 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Barclays lowered their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Raymond James reaffirmed an “outperform” rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $607.43.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

TMO opened at $412.15 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The firm has a market capitalization of $155.58 billion, a PE ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm’s 50-day moving average price is $453.88 and its 200 day moving average price is $510.15.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the previous year, the firm posted $5.11 EPS. The business’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date was Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.